0000885590-13-000062.txt : 20130730 0000885590-13-000062.hdr.sgml : 20130730 20130730175307 ACCESSION NUMBER: 0000885590-13-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130726 FILED AS OF DATE: 20130730 DATE AS OF CHANGE: 20130730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weldon Ryan CENTRAL INDEX KEY: 0001564233 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 13996986 MAIL ADDRESS: STREET 1: 4787 LEVY STREET CITY: MONTREAL STATE: A8 ZIP: H4R 2P9 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2013-07-26 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001564233 Weldon Ryan 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8 QUEBEC, CANADA 0 1 0 0 EVP, Company Group Chairman Common Stock, no par value 2013-07-26 4 M 0 5173 0 A 68611 D Common Stock, no par value 2013-07-26 4 F 0 2683 0 D 65928 D Restricted Share Units 2013-07-26 4 M 0 5173 0 D Common Stock 5173 15521 D This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the 20 trading days starting on each measurement dates: 25% on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSUs have already paid out for the first two of the three potential shares of common stock. This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1. This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units. by: Nicholas Zanoni for Ryan Weldon 2013-07-30